Fig. 3From: Long-term outcomes of intravitreal anti-VEGF therapies in patients affected by neovascular age-related macular degeneration: a real-life studyMean ± SEM BCVA expressed as an ETDRS letter score over the five-year study period for patients treated with Ranibizumab, Aflibercept, and Bevacizumab. **p < 0.01 versus baseline, ***p < 0.001 versus baseline, Dunnett’s multiple comparison testBack to article page